OpenNashEarnings

Pharmaceuticals · NYSE: ZTS

Zoetis earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 11 Feb 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Zoetis slowed U.S. dermatology share loss to 4 points through targeted promotions and advanced long-acting Cytopoint and Simparica Duo toward approval, while Livestock and Diagnostics offset pet-owner weakness.

Companion Animal stayed under pressure from higher vet costs, fewer clinic visits and new competitors in dermatology and parasiticides. Zoetis answered with promotions that cut U.S. dermatology share loss from 7 to 4 points a quarter. Livestock grew on cattle, fish and vaccines, and Diagnostics grew through the VitalRADS and Veterinary Pathology Group acquisitions. Lenivia and Portela launched in the EU, Canada and Great Britain.

Read the Q3 2026 summary →Q3 2026 slides (PDF) ↗Official transcript (PDF) ↗

Quarters

KPI history

Revenue$2.4B−1.3% y/yQ3 2026
Q4 2024: $2.3B (worked out from the annual figure)Q4 ’24$2.3BQ1 2025: $2.2BQ1 ’25$2.2BQ2 2025: $2.5BQ2 ’25$2.5BQ3 2025: $2.4BQ3 ’25$2.4BQ4 2025: $2.4B (worked out from the annual figure)Q4 ’25$2.4BQ1 2026: $2.3BQ1 ’26$2.3BQ2 2026: $2.5BQ2 ’26$2.5BQ3 2026: $2.4BQ3 ’26$2.4B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$2.3B *
Q1 2025$2.2B
Q2 2025$2.5B
Q3 2025$2.4B
Q4 2025$2.4B *
Q1 2026$2.3B
Q2 2026$2.5B
Q3 2026$2.4B
Diluted EPS (GAAP)$1.44−11.7% y/yQ3 2026
Q1 2025: $1.34Q1 ’25$1.34Q2 2025: $1.63Q2 ’25$1.63Q3 2025: $1.63Q3 ’25$1.63Q1 2026: $1.42Q1 ’26$1.42Q2 2026: $1.65Q2 ’26$1.65Q3 2026: $1.44Q3 ’26$1.44
Data
Q1 2025$1.34
Q2 2025$1.63
Q3 2025$1.63
Q1 2026$1.42
Q2 2026$1.65
Q3 2026$1.44

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Free cash flow$717.0M−10.2% y/yQ3 2026
Q4 2024: $689.0MQ4 ’24$689.0MQ1 2025: $337.0MQ1 ’25$337.0MQ2 2025: $459.0MQ2 ’25$459.0MQ3 2025: $798.0MQ3 ’25$798.0MQ4 2025: $689.0MQ4 ’25$689.0MQ1 2026: $291.0MQ1 ’26$291.0MQ2 2026: $538.0MQ2 ’26$538.0MQ3 2026: $717.0MQ3 ’26$717.0M
Data
Q4 2024$689.0M
Q1 2025$337.0M
Q2 2025$459.0M
Q3 2025$798.0M
Q4 2025$689.0M
Q1 2026$291.0M
Q2 2026$538.0M
Q3 2026$717.0M

Operating cash flow minus capital expenditure, from cash flow statements.

Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Revenue$2.3Bd$2.2B$2.5B$2.4B$2.4Bd$2.3B$2.5B$2.4B
Net income$581.0Md$602.0M$726.0M$721.0M$624.0Md$601.0M$691.0M$591.0M
Diluted EPS—$1.34$1.63$1.63—$1.42$1.65$1.44
Operating cash flow$905.0Md$515.0M$605.0Md$936.0Md$848.0Md$401.0M$655.0Md$824.0Md
Capital expenditure$216.0Md$178.0M$146.0Md$138.0Md$159.0Md$110.0M$117.0Md$107.0Md
Free cash flow$689.0M$337.0M$459.0M$798.0M$689.0M$291.0M$538.0M$717.0M
R&D expense$186.0Md$162.0M$166.0M$175.0M$195.0Md$180.0M$173.0M$174.0M

From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.

10-K and 10-Q filings